| The role of Endocan as a Prognostic Biomarker in community-acquired pneumonia S Gunaydin, M Kucuk, UM Gunaydin Pakistan Journal of Medical Sciences 35 (1), 117, 2019 | 7 | 2019 |
| Factors associated with delayed diagnosis and treatment in patients with cancer. IN Okten, B Aktas Sezen, UM Gunaydin, S Koca, T Ozturk, HT Ozder, ... Journal of Clinical Oncology 36 (15_suppl), e22141-e22141, 2018 | 6 | 2018 |
| Analysis of feasibility of geriatric assessment tools in elderly cancer patients and effects on anti-cancer treatment planning. UM Gunaydin, A Tufan Cincin, S Gunaydin, F Dane, N Babacan, ... Journal of Clinical Oncology 36 (15_suppl), e22028-e22028, 2018 | 4 | 2018 |
| Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer. U Isik, O Kostek, G Demiray, A Dirican, M Simsek, M Büyüksimsek, G Ucar, ... Journal of Clinical Oncology 37 (15_suppl), e16075-e16075, 2019 | 3 | 2019 |
| Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study A Bilici, S Koca, M Karaagac, SG Aydin, E Eraslan, MA Kaplan, B Ocak, ... Journal of Cancer Research and Clinical Oncology 149 (11), 8243-8253, 2023 | 2 | 2023 |
| A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a trispecific Humabody® T-cell enhancer, in … JS de Bono, HT Arkenau, EH Gort, LA Devriese, E Fontana, DG Knapen, ... prostate 1, 2, 2022 | 1 | 2022 |
| Neoadjuvant treatment in patients with locally advanced gastric cancer. M Gumus, S Kaya, S Eris, O Alan, TA Telli, IN Okten, UM Gunaydin, ... Journal of Clinical Oncology 37 (4_suppl), 127-127, 2019 | 1 | 2019 |
| Abstract CT207: A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T … JS de Bono, HT Arkenau, EH Gort, LL Devriese, E Fontana, DG Knapen, ... Cancer Research 82 (12_Supplement), CT207-CT207, 2022 | | 2022 |
